Skip to content

FBDIX

Franklin Biotechnology Discovery Fund

Factsheet
View All
As of 12/11/2025

NAV 1

$185.43

$1.02 (0.55%)
 

POP 2

$196.22

 
 

YTD Total Return At NAV 3

54.00%

 
As of 11/30/2025

Morningstar Overall Rating™ 4

View ratings details
Health

See the risks and other important information.

Overview

  • Fund Description
  • Strategy & Benefits
  • Investment Philosophy, Strategy and Approach

Fund Description

The fund seeks capital appreciation by investing at least 80% of its net assets in securities of biotechnology companies and discovery research firms including those involved in fields such as genomics, genetic engineering, and gene therapy, as well as health care, pharmaceuticals and agriculture.

Strategy Statement

"With the increasing demand for new medical treatments driving earnings growth, and many profitable firms to choose from, we believe now is an exciting time to invest in the biotechnology sector."

Evan McCulloch, CFA®

Strategy & Benefits

Strategy
  • We take a bottom-up approach to individual stock selection.
  • We look for companies that possess products with favorable competitive profiles, large market opportunities and strong intellectual property.
  • We favor companies with excellent management, strong financial characteristics and attractive valuations.
  • Our San Francisco Bay Area location is shared by many leading biotechnology companies, enabling us to easily attend scientific meetings and symposia, and to consult with community and academic physicians. 
Benefits
  • Participate in trends moving markets. Invest in innovative sectors—technology, medicine, global communications—we believe are poised for long-term growth.
  • Diversification. By adding investments from different sectors to your portfolio, you may take advantage of expanding and contracting economic cycles.
  • Experienced management. Same lead portfolio manager since the fund's inception in 1997.

Investment Philosophy, Strategy and Approach

Investment Philosophy

The Franklin Equity Group philosophy holds that companies with the potential for long-term sustainable growth can provide significant opportunities for investors. Market participants can have a short-term perspective and may under appreciate the potential for value created by sustainable growth. We believe that we have the potential to deliver attractive risk-adjusted returns by identifying companies with potential for sustainable growth which we believe is not reflected in current prices.

Investment Process

Within a collaborative environment, our team utilizes fundamental, bottom-up research to focus on companies that we believe have sustainable growth characteristics—meeting our criteria of Growth, Quality and Valuation.

GROWTH:

  • Focus on companies with potential to produce sustainable earnings and cash flow growth
  • Evaluate the long-term market opportunity and competitive structure of the industry seeking to identify target leaders and emerging leaders

QUALITY:

  • Seek companies with strong and improving competitive positions in attractive markets
  • Identify experienced and talented management teams as well as financial strength reflected in the capital structure, gross and operating margins, free cash flow generation, and returns on capital

VALUATION:

  • Consider a range of potential outcomes based on an assessment of multiple scenarios
  • Evaluate whether, in our view, security prices fully reflect the balance of the sustainable growth opportunities relative to the business and financial risks
Fund Information
Asset Class 
Equity
Share Class Inception Date 
09/15/1997
Fund Inception Date 
09/15/1997
Benchmark 
NASDAQ Biotechnology Index
Additional Benchmark 
S&P 500 Index
Investment Style 
Sector
Morningstar Category4 
Health
Lipper Classification 
Health/Biotechnology Funds
Dividend Frequency, if any 
Annually
Total Net Assets  As of 11/30/2025 (Updated Monthly)
$1.06 Billion
Portfolio Turnover 
22%
Sales Charges, Expenses & Fees
As of 09/01/2025
Gross Expense Ratio5 
1.03%
Net Expense Ratio5, 6 
1.02%
Maximum Initial Charge 
5.50%
CDSC7 
1.00%
12b-1 Fee 
0.25%
Identifiers
Ticker 
FBDIX
Fund Number 
402
CUSIP Code 
354713844

Portfolio Managers

Evan McCulloch, CFA®

California, United States

Managed Fund Since 1997

Akiva Felt

California, United States

Managed Fund Since 2020

Performance

  • Average Annual Total Returns
  • Calendar Year Returns
  • Cumulative Total Returns
  • Risk Measures

Average Annual Total Returns

Average Annual Total Returns 8, 9

 As of 11/30/2025

Chart

Bar chart with 4 data series.
The chart has 1 X axis displaying categories.
The chart has 1 Y axis displaying values. Data ranges from 5.02 to 44.74.
End of interactive chart.

Month End   As of 11/30/2025
Class A - With Sales Charge (POP) (%)
1 Year  
36.79
3 Years  
20.14
5 Years  
6.04
10 Years  
6.46
Since Inception   09/15/1997
10.71
Month End   As of 11/30/2025
Class A - Without Sales Charge (NAV) (%)
1 Year  
44.74
3 Years  
22.43
5 Years  
7.25
10 Years  
7.07
Since Inception   09/15/1997
10.94
Month End   As of 11/30/2025
NASDAQ Biotechnology Index (%)
1 Year  
25.26
3 Years  
10.23
5 Years  
5.02
10 Years  
5.22
Since Inception   09/15/1997
10.81
Month End   As of 11/30/2025
S&P 500 Index (%)
1 Year  
15.00
3 Years  
20.57
5 Years  
15.28
10 Years  
14.63
Since Inception   09/15/1997
9.34

Performance data quoted represents past performance, which does not guarantee future results. Current performance may be lower or higher than the figures shown. Principal value and investment returns will fluctuate, and investors' shares, when redeemed, may be worth more or less than the original cost. Performance would have been lower if fees had not been waived in various periods. Total returns assume the reinvestment of all distributions and the deduction of all Fund expenses. Returns with sales charge reflect a deduction of the stated maximum sales charge. Returns without sales charge would have been lower had sales charges been reflected. An investor cannot invest directly in an index, and unmanaged index returns do not reflect any fees, expenses or sales charges. Returns for periods of less than one year are not annualized. 

See the risks and other important information.


Calendar Year Returns

Calendar Year Returns 8, 9

 As of 11/30/2025

Chart

Bar chart with 4 data series.
The chart has 1 X axis displaying categories.
The chart has 1 Y axis displaying values. Data ranges from -22.23 to 34.84.
End of interactive chart.

Month End   As of 11/30/2025
Class A - With Sales Charge (POP) (%)
YTD  
46.28
2024  
-1.72
2023  
11.89
2022  
-17.46
2021  
-22.23
2020  
22.75
2019  
27.43
2018  
-20.35
2017  
11.97
2016  
-21.92
2015  
-0.57
Performance Inception Date  
09/15/1997
Month End   As of 11/30/2025
Class A - Without Sales Charge (NAV) (%)
YTD  
54.80
2024  
4.00
2023  
18.40
2022  
-12.66
2021  
-17.70
2020  
29.89
2019  
34.84
2018  
-15.72
2017  
18.80
2016  
-17.16
2015  
5.50
Performance Inception Date  
09/15/1997
Month End   As of 11/30/2025
NASDAQ Biotechnology Index (%)
YTD  
34.97
2024  
-1.37
2023  
3.74
2022  
-10.91
2021  
-0.63
2020  
25.69
2019  
24.41
2018  
-9.32
2017  
21.06
2016  
-21.68
2015  
11.42
Performance Inception Date  
—
Month End   As of 11/30/2025
S&P 500 Index (%)
YTD  
17.81
2024  
25.02
2023  
26.29
2022  
-18.11
2021  
28.71
2020  
18.40
2019  
31.49
2018  
-4.38
2017  
21.83
2016  
11.96
2015  
1.38
Performance Inception Date  
—

Performance data quoted represents past performance, which does not guarantee future results. Current performance may be lower or higher than the figures shown. Principal value and investment returns will fluctuate, and investors' shares, when redeemed, may be worth more or less than the original cost. Performance would have been lower if fees had not been waived in various periods. Total returns assume the reinvestment of all distributions and the deduction of all Fund expenses. Returns with sales charge reflect a deduction of the stated maximum sales charge. Returns without sales charge would have been lower had sales charges been reflected. An investor cannot invest directly in an index, and unmanaged index returns do not reflect any fees, expenses or sales charges. Returns for periods of less than one year are not annualized. 

See the risks and other important information.


Cumulative Total Returns

Cumulative Total Returns 8, 9

 As of 11/30/2025

The hypothetical growth scenario of $10,000 does not reflect the deduction of brokerage commissions or taxes that investors may pay on distributions or the sale of shares. Had they been reflected hypothetical values would be lower.

Chart

Line chart with 3 lines.
The chart has 1 X axis displaying Time. Data ranges from 1997-09-01 00:00:00 to 2025-11-01 00:00:00.
The chart has 1 Y axis displaying values. Data ranges from 7086.19 to 186843.43.
End of interactive chart.

Month End   As of 11/30/2025
Class A - With Sales Charge (POP) (%)
YTD  
46.28
1 Year  
36.79
3 Years  
73.41
5 Years  
34.10
10 Years  
87.10
15 Years  
571.06
Since Inception   09/15/1997
1,665.35
Month End   As of 11/30/2025
Class A - Without Sales Charge (NAV) (%)
YTD  
54.80
1 Year  
44.74
3 Years  
83.51
5 Years  
41.90
10 Years  
97.99
15 Years  
610.14
Since Inception   09/15/1997
1,768.44
Month End   As of 11/30/2025
NASDAQ Biotechnology Index (%)
YTD  
34.97
1 Year  
25.26
3 Years  
33.93
5 Years  
27.74
10 Years  
66.32
15 Years  
547.16
Since Inception   09/15/1997
1,708.68
Month End   As of 11/30/2025
S&P 500 Index (%)
YTD  
17.81
1 Year  
15.00
3 Years  
75.28
5 Years  
103.57
10 Years  
291.75
15 Years  
667.53
Since Inception   09/15/1997
1,141.47

Historical Cumulative Total Returns

Date Selected   As of 11/30/2025
Class A - With Sales Charge (POP) (%)
YTD  
46.28
1 Year  
36.79
3 Years  
73.41
5 Years  
34.10
10 Years  
87.10
15 Years  
571.06
Since Inception   09/15/1997
1,665.35
Date Selected   As of 11/30/2025
Class A - Without Sales Charge (NAV) (%)
YTD  
54.80
1 Year  
44.74
3 Years  
83.51
5 Years  
41.90
10 Years  
97.99
15 Years  
610.14
Since Inception   09/15/1997
1,768.44
Date Selected   As of 11/30/2025
NASDAQ Biotechnology Index (%)
YTD  
34.97
1 Year  
25.26
3 Years  
33.93
5 Years  
27.74
10 Years  
66.32
15 Years  
547.16
Since Inception   09/15/1997
1,708.68
Date Selected   As of 11/30/2025
S&P 500 Index (%)
YTD  
17.81
1 Year  
15.00
3 Years  
75.28
5 Years  
103.57
10 Years  
291.75
15 Years  
667.53
Since Inception   09/15/1997
1,141.47

Performance data quoted represents past performance, which does not guarantee future results. Current performance may be lower or higher than the figures shown. Principal value and investment returns will fluctuate, and investors' shares, when redeemed, may be worth more or less than the original cost. Performance would have been lower if fees had not been waived in various periods. Total returns assume the reinvestment of all distributions and the deduction of all Fund expenses. Returns with sales charge reflect a deduction of the stated maximum sales charge. Returns without sales charge would have been lower had sales charges been reflected. An investor cannot invest directly in an index, and unmanaged index returns do not reflect any fees, expenses or sales charges. Returns for periods of less than one year are not annualized. 

See the risks and other important information.

If the sales charge (if applicable) had been included, the return would have been lower. 


Risk Measures

Risk Measures8, 9

 As of 11/30/2025
Measured against: NASDAQ Biotechnology Index
Statistics 3 Years 5 Years 10 Years
Beta1.141.02 1.04
Beta Bear0.710.70 0.95
Bull Bear Capture Ratio1.521.12 1.10
Beta Bull1.170.93 0.94
Historical Tracking Error8.409.26 7.82
Information Ratio1.450.24 0.24
Standard Deviation (%) 3 Years 5 Years 10 Years
Class A - Without Sales Charge (NAV)20.5519.88 22.57
NASDAQ Biotechnology Index 16.5217.12 20.43
Sharpe Ratio (%) 3 Years 5 Years 10 Years
Class A - Without Sales Charge (NAV)0.860.21 0.22

Performance data quoted represents past performance, which does not guarantee future results. Current performance may be lower or higher than the figures shown. Principal value and investment returns will fluctuate, and investors' shares, when redeemed, may be worth more or less than the original cost. Performance would have been lower if fees had not been waived in various periods. Total returns assume the reinvestment of all distributions and the deduction of all Fund expenses. Returns with sales charge reflect a deduction of the stated maximum sales charge. Returns without sales charge would have been lower had sales charges been reflected. An investor cannot invest directly in an index, and unmanaged index returns do not reflect any fees, expenses or sales charges. Returns for periods of less than one year are not annualized. 

See the risks and other important information.


Portfolio

Assets

As of 11/30/2025 Updated Monthly
Total Net Assets 
$1.06 Billion

Positions

As of 11/30/2025 Updated Monthly
Number of Issuers 
82

Portfolio Statistics

As of 11/30/2025 Updated Monthly
 FundBenchmark
Price to Earnings (12-Month Forward) 20.78x18.43x
Weighted Average Market Capitalization (USD) $58.98 Billion$62.41 Billion
Price to Cash Flow 17.91x19.90x
Price to Book 5.52x5.05x

Portfolio Allocations

  • Assets
  • Geography
  • Sector
  • Market Capitalization

Assets

Asset Allocation

As of 11/30/2025 % of Total Updated Monthly

Chart

Bar chart with 2 bars.
The chart has 1 X axis displaying categories.
The chart has 1 Y axis displaying values. Data ranges from 2.1257 to 97.8743.
End of interactive chart.
Fund
Equity 97.87%
Cash & Cash Equivalents 2.13%

Geography

Geographic Allocation

As of 11/30/2025 % of Total Updated Monthly

Chart

Bar chart with 2 data series.
The chart has 1 X axis displaying categories.
The chart has 1 Y axis displaying values. Data ranges from 0.0684 to 100.
End of interactive chart.
Fund Benchmark
United States 81.94% 100.00%
Netherlands 5.60% —
Denmark 3.13% —
France 2.53% —
United Kingdom 1.79% —
Australia 1.60% —
Canada 0.83% —
Germany 0.25% —
Sweden 0.13% —
South Korea 0.07% —
Cash 2.13% —

Sector

Sector Allocation

As of 11/30/2025 % of Total Updated Monthly

Chart

Bar chart with 2 data series.
The chart has 1 X axis displaying categories.
The chart has 1 Y axis displaying values. Data ranges from 0.2383 to 80.1962.
End of interactive chart.
Fund Benchmark
Biotechnology 78.31% 80.20%
Pharmaceuticals 15.82% 13.78%
Health Care Services 2.55% 1.16%
Life Sciences Tools & Services 0.96% 4.75%
Managed Health Care 0.24% —
Cash & Cash Equivalents 2.13% —

Market Capitalization

Market Capitalization Allocation

As of 11/30/2025 % of Equity Updated Monthly

Chart

Bar chart with 7 bars.
The chart has 1 X axis displaying categories.
The chart has 1 Y axis displaying values. Data ranges from 0.7285 to 30.6443.
End of interactive chart.
Fund
<2.0 Billion 21.95%
2.0-5.0 Billion 18.23%
5.0-10.0 Billion 7.38%
10.0-25.0 Billion 16.81%
25.0-50.0 Billion 4.25%
>50.0 Billion 30.64%
N/A 0.73%

Portfolio Holdings

  • Holdings
  • Top Ten Holdings

Holdings

Holdings

As of 10/31/2025 Updated Monthly
Security Name 
Gilead Sciences Inc COM USD0.001
Weight (%) 
5.57
Market Value ($) 
53,146,391
Quantity 
443,663
Security Name 
Vertex Pharmaceuticals Inc COM USD.01
Weight (%) 
4.56
Market Value ($) 
43,471,976
Quantity 
102,150
Security Name 
Amgen Inc COM USD.0001
Weight (%) 
4.49
Market Value ($) 
42,812,171
Quantity 
143,458
Security Name 
Argenx SE SPONSORED ADR
Weight (%) 
4.14
Market Value ($) 
39,461,522
Quantity 
48,212
Security Name 
Regeneron Pharmaceuticals Inc COM USD.001
Weight (%) 
4.09
Market Value ($) 
39,057,160
Quantity 
59,922
Security Name 
Jazz Pharmaceuticals PLC ORD USD.0001
Weight (%) 
4.02
Market Value ($) 
38,333,428
Quantity 
278,505
Security Name 
Alnylam Pharmaceuticals Inc COM USD.01
Weight (%) 
3.83
Market Value ($) 
36,539,749
Quantity 
80,124
Security Name 
Franklin Institutional U.S. Government Money Market Fund OEMF-SWEEP MONEY MARKET PORTFOLIO
Weight (%) 
3.78
Market Value ($) 
36,072,290
Quantity 
36,072,290
Security Name 
Insmed Inc COM USD.01
Weight (%) 
3.75
Market Value ($) 
35,764,817
Quantity 
188,633
Security Name 
Praxis Precision Medicines Inc COM USD 0.0001
Weight (%) 
3.08
Market Value ($) 
29,402,766
Quantity 
147,931

Portfolio holdings are based on the total portfolio and are subject to change at any time. Holdings are provided for informational purposes only and should not be construed as a recommendation to purchase or sell any security. 

Top Ten Holdings

Top Equity Issuers

As of 11/30/2025 Updated Monthly

Chart

Bar chart with 10 bars.
The chart has 1 X axis displaying categories.
The chart has 1 Y axis displaying values. Data ranges from 2.7404 to 5.2644.
End of interactive chart.
Fund
GILEAD SCIENCES INC 5.26%
JAZZ PHARMACEUTICALS PLC 4.71%
AMGEN INC 4.67%
REGENERON PHARMACEUTICALS INC 4.49%
ARGENX SE 4.21%
VERTEX PHARMACEUTICALS INC 4.18%
INSMED INC 3.70%
ALNYLAM PHARMACEUTICALS INC 3.41%
PTC THERAPEUTICS INC 3.05%
PRAXIS PRECISION MEDICINES INC 2.74%

Portfolio holdings are based on the total portfolio and are subject to change at any time. Holdings are provided for informational purposes only and should not be construed as a recommendation to purchase or sell any security. 

Distributions & Tax

  • Distributions
  • Tax Information

Distributions

Distribution Schedules

Dividend Frequency, if any This fund is an ex-Dividend fund
Annually
Capital Gain Distributions 
December

Proposed 2025 distribution dates for Franklin, Templeton and Mutual Series funds (excluding ETFs).

Final composition of the current year’s distribution—income, capital gains and/or return of capital—are based on US tax rules and will be determined by February of the following year. For tax characterization of a distribution, such as return of capital and tax-exempt income, click on the “Tax Information” tab above.

Distributions Per Share

Current Year Distributions Per Share
Distributions with future dates are estimates and those figures are not final
Record Date  
12/19/2025
Ex-Dividend Date  
12/22/2025
Reinvestment Date  
12/22/2025
Payable Date  
12/22/2025
Reinvestment Amount  
—
Long-Term Capital Gains  
$13.6940-$15.0630 Estimates
Short-Term Capital Gains  
$0.6040-$0.7040 Estimates
Income  
—
Total Distribution Per Share  
— Estimates
Historical Distributions Per Share
Since Inception Year
  • 2024
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2000
  • 1999
  • 1998
  • 1997
  • Since Inception
Record Date  
12/19/2024
Ex-Dividend Date  
12/20/2024
Reinvestment Date  
12/20/2024
Payable Date  
12/20/2024
Reinvestment Amount  
$120.72
Long-Term Capital Gains  
$7.9461
Short-Term Capital Gains  
$3.8146
Income  
—
Total Distribution Per Share  
$11.7607
Record Date  
12/19/2022
Ex-Dividend Date  
12/20/2022
Reinvestment Date  
12/20/2022
Payable Date  
12/20/2022
Reinvestment Amount  
$107.06
Long-Term Capital Gains  
—
Short-Term Capital Gains  
—
Income  
$0.1411
Total Distribution Per Share  
$0.1411
Record Date  
12/14/2021
Ex-Dividend Date  
12/15/2021
Reinvestment Date  
12/15/2021
Payable Date  
12/15/2021
Reinvestment Amount  
$120.68
Long-Term Capital Gains  
$15.4906
Short-Term Capital Gains  
$1.1815
Income  
$1.011
Total Distribution Per Share  
$17.6831
Record Date  
12/14/2020
Ex-Dividend Date  
12/15/2020
Reinvestment Date  
12/15/2020
Payable Date  
12/15/2020
Reinvestment Amount  
$172.97
Long-Term Capital Gains  
$14.4512
Short-Term Capital Gains  
$10.3921
Income  
—
Total Distribution Per Share  
$24.8433
Record Date  
12/13/2019
Ex-Dividend Date  
12/16/2019
Reinvestment Date  
12/16/2019
Payable Date  
12/18/2019
Reinvestment Amount  
$151.39
Long-Term Capital Gains  
$14.1643
Short-Term Capital Gains  
—
Income  
—
Total Distribution Per Share  
$14.1643
Record Date  
12/14/2018
Ex-Dividend Date  
12/17/2018
Reinvestment Date  
12/17/2018
Payable Date  
12/19/2018
Reinvestment Amount  
$127.77
Long-Term Capital Gains  
$2.2068
Short-Term Capital Gains  
$2.3428
Income  
—
Total Distribution Per Share  
$4.5496
Record Date  
12/14/2017
Ex-Dividend Date  
12/15/2017
Reinvestment Date  
12/15/2017
Payable Date  
12/19/2017
Reinvestment Amount  
$147.37
Long-Term Capital Gains  
$2.5086
Short-Term Capital Gains  
$1.0883
Income  
—
Total Distribution Per Share  
$3.5969
Record Date  
12/14/2016
Ex-Dividend Date  
12/15/2016
Reinvestment Date  
12/15/2016
Payable Date  
12/19/2016
Reinvestment Amount  
$132.12
Long-Term Capital Gains  
$4.2035
Short-Term Capital Gains  
—
Income  
$1.7284
Total Distribution Per Share  
$5.9319
Record Date  
12/14/2015
Ex-Dividend Date  
12/15/2015
Reinvestment Date  
12/15/2015
Payable Date  
12/17/2015
Reinvestment Amount  
$157.61
Long-Term Capital Gains  
$9.9589
Short-Term Capital Gains  
$3.8182
Income  
—
Total Distribution Per Share  
$13.7771
Record Date  
12/12/2014
Ex-Dividend Date  
12/15/2014
Reinvestment Date  
12/15/2014
Payable Date  
12/17/2014
Reinvestment Amount  
$162.67
Long-Term Capital Gains  
$2.9405
Short-Term Capital Gains  
$3.7275
Income  
—
Total Distribution Per Share  
$6.668
Record Date  
12/13/2013
Ex-Dividend Date  
12/16/2013
Reinvestment Date  
12/16/2013
Payable Date  
12/18/2013
Reinvestment Amount  
$124.75
Long-Term Capital Gains  
$7.2093
Short-Term Capital Gains  
$1.5839
Income  
—
Total Distribution Per Share  
$8.7932
Record Date  
12/14/2012
Ex-Dividend Date  
12/17/2012
Reinvestment Date  
12/17/2012
Payable Date  
12/19/2012
Reinvestment Amount  
$84.84
Long-Term Capital Gains  
—
Short-Term Capital Gains  
—
Income  
$0.0692
Total Distribution Per Share  
$0.0692
Record Date  
12/27/2011
Ex-Dividend Date  
12/28/2011
Reinvestment Date  
12/28/2011
Payable Date  
12/30/2011
Reinvestment Amount  
$63.34
Long-Term Capital Gains  
$9.2805
Short-Term Capital Gains  
$0.0272
Income  
$0.5152
Total Distribution Per Share  
$9.8229
Record Date  
12/14/2000
Ex-Dividend Date  
12/15/2000
Reinvestment Date  
12/15/2000
Payable Date  
12/19/2000
Reinvestment Amount  
$72.53
Long-Term Capital Gains  
$0.1884
Short-Term Capital Gains  
—
Income  
—
Total Distribution Per Share  
$0.1884
Record Date  
12/14/1999
Ex-Dividend Date  
12/15/1999
Reinvestment Date  
12/15/1999
Payable Date  
12/28/1999
Reinvestment Amount  
$38.84
Long-Term Capital Gains  
—
Short-Term Capital Gains  
$0.0637
Income  
—
Total Distribution Per Share  
$0.0637
Record Date  
12/14/1998
Ex-Dividend Date  
12/15/1998
Reinvestment Date  
12/15/1998
Payable Date  
12/28/1998
Reinvestment Amount  
$23.52
Long-Term Capital Gains  
—
Short-Term Capital Gains  
$0.4207
Income  
—
Total Distribution Per Share  
$0.4207
Record Date  
12/26/1997
Ex-Dividend Date  
12/26/1997
Reinvestment Date  
—
Payable Date  
12/26/1997
Reinvestment Amount  
$23.44
Long-Term Capital Gains  
—
Short-Term Capital Gains  
$0.047
Income  
—
Total Distribution Per Share  
$0.047

Annually, a fund must distribute all realized capital gains net of realized losses, so the fund will not be subject to an entity level income tax. A fund’s capital gain distribution in a particular year may be a result of the disposition of holdings that appreciated in value during prior years. Thus, while the fund may gain or lose value over the course of a year, a capital gain distribution paid by the fund may not be indicative of current performance of the fund.

The distributable amount of net capital gains are paid on a per-share basis to all investors who hold shares of the fund on the record date of the distribution and are recognized by the shareholder for tax purposes as of the ex-date of the distribution, regardless of when the gains or losses arose in the fund. Net gains on holdings held long term by the fund would be distributed to shareholders as a long-term capital gain distribution no matter how long the shareholder has owned shares in the fund.

Refer to the fund’s annual report or statement of additional information for specific information regarding distributions.

Tax Information

Tax Information

Federal ID Number 94-3273632
For information on tax years prior to 2008, please contact us
These amounts represent distributions paid by the fund, foreign taxes passed through (if any), and other distribution characteristics for the calendar year selected. These amounts are reported to shareholders on Form 1099-DIV.
Distributions per Share ($)
2024 Year
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
Record Date  
Dec 19
Ordinary Dividends  
3.8146
Qualified Dividends  
0.638946
Capital Gain Distributions  
7.9461
Unrecaptured Section 1250 Gain  
—
Non-Taxable Return Of Capital  
—
Section 199a Dividends  
—
Foreign Tax Paid  
—
Exempt Interest Dividends  
—
Interest on Tax Reclaim Refunds  
—
Record Date  
Ordinary Dividends  
3.8146
Qualified Dividends  
0.638946
Capital Gain Distributions  
7.9461
Unrecaptured Section 1250 Gain  
—
Non-Taxable Return Of Capital  
—
Section 199a Dividends  
—
Foreign Tax Paid  
—
Exempt Interest Dividends  
—
Interest on Tax Reclaim Refunds  
—
Supplemental Tax Information
Foreign Source Income 
—
Foreign Source Qualified Dividends 
—
Direct U.S. Government Obligations 
—
Specified Private Activity Bond Interest 
—
Dividends Received Deduction 
14.33%
Section 163(j) 
—
Indiana Resident Taxable Income 
—
Utah Resident Taxable Income 
—

Franklin Templeton and its specialized investment managers and its employees are not in the business of providing tax or legal advice to taxpayers. These materials and any tax-related statements are not intended or written to be used, and cannot be used or relied upon, by any such taxpayer for the purpose of avoiding tax penalties or complying with any applicable tax laws or regulations. Tax-related statements, if any, may have been written in connection with the promotion or marketing of the transaction(s) or matter(s) addressed by these materials, to the extent allowed by applicable law. Each investor’s tax situation is different, and is based on an individual’s tax bracket, type of account used for investment and other factors. Any such taxpayer should seek advice based on the taxpayer's particular circumstances from an independent tax advisor.

Pricing

Pricing History Chart

As of 12/11/2025 Updated Daily
Since Inception Time Period
  • 1 Month
  • 3 Months
  • 6 Months
  • YTD
  • 1 Year
  • 3 Years
  • 5 Years
  • Since Inception

Chart

Line chart with 7257 data points.
The chart has 1 X axis displaying Time. Data ranges from 1997-09-15 00:00:01 to 2025-12-11 00:00:01.
The chart has 1 Y axis displaying values. Data ranges from 17.68 to 216.54.
End of interactive chart.

Daily Fund Prices and Breakpoints

As of 12/11/2025

Share Prices

As of 12/11/2025
NAV1 (Net Asset Value)
$185.43
NAV Change1 
$1.02
NAV Change (%)1 
0.55%
POP2 (Public Offering Price)
$196.22

52-Week Range

Highest NAV  As on 11/28/2025
$186.39
Lowest NAV  As on 04/08/2025
$99.30
POP and Sales Charge at Breakpoints

Investment

Sales Charge

POP

Less than $25,000 5.50%$196.22
$25,000 - $49,999 5.25%$195.70
$50,000 - $99,999 4.50%$194.17
$100,000 - $249,999 3.50%$192.16
$250,000 - $499,999 2.50%$190.18
$500,000 - $749,999 2.00%$189.21
$750,000 - $999,999 1.50%$188.25
POP and Sales Charge at Breakpoints
Investment  
Less than $25,000
Sales Charge  
5.50%
POP  
$196.22
Investment  
$25,000 - $49,999
Sales Charge  
5.25%
POP  
$195.70
Investment  
$50,000 - $99,999
Sales Charge  
4.50%
POP  
$194.17
Investment  
$100,000 - $249,999
Sales Charge  
3.50%
POP  
$192.16
Investment  
$250,000 - $499,999
Sales Charge  
2.50%
POP  
$190.18
Investment  
$500,000 - $749,999
Sales Charge  
2.00%
POP  
$189.21
Investment  
$750,000 - $999,999
Sales Charge  
1.50%
POP  
$188.25
Historical Data - Daily Fund Prices
1 Month Time Period
  • 1 Month
  • 3 Months
  • 6 Months
  • YTD
  • 1 Year
  • 3 Years
  • 5 Years
  • Since Inception
NAV  As of 12/11/2025
$185.43 (USD)
POP  As of 12/11/2025
$196.22 (USD)
Highest NAV  As of 11/28/2025
$186.39 (USD)
Lowest NAV  As of 11/13/2025
$167.52 (USD)

Historical Pricing Results   From   11/11/2025   To   12/11/2025

Date 
12/11/2025
NAV  
$185.43
POP  
$196.22
NAV Change  
$1.02
NAV Change (%)  
0.55%
Date 
12/10/2025
NAV  
$184.41
POP  
$195.14
NAV Change  
$2.45
NAV Change (%)  
1.35%
Date 
12/09/2025
NAV  
$181.96
POP  
$192.55
NAV Change  
$-3.81
NAV Change (%)  
-2.05%
Date 
12/08/2025
NAV  
$185.77
POP  
$196.58
NAV Change  
$2.33
NAV Change (%)  
—
Date 
12/05/2025
NAV  
$183.44
POP  
$194.12
NAV Change  
$0.64
NAV Change (%)  
0.35%
Date 
12/04/2025
NAV  
$182.80
POP  
$193.44
NAV Change  
$1.30
NAV Change (%)  
0.72%
Date 
12/03/2025
NAV  
$181.50
POP  
$192.06
NAV Change  
$3.25
NAV Change (%)  
1.82%
Date 
12/02/2025
NAV  
$178.25
POP  
$188.62
NAV Change  
$-2.79
NAV Change (%)  
-1.54%
Date 
12/01/2025
NAV  
$181.04
POP  
$191.58
NAV Change  
$-5.35
NAV Change (%)  
-2.87%
Date 
11/28/2025
NAV  
$186.39
POP  
$197.24
NAV Change  
$0.27
NAV Change (%)  
0.15%
Date 
11/27/2025
NAV  
$186.12
POP  
$196.95
NAV Change  
$1.80
NAV Change (%)  
0.00%
Date 
11/26/2025
NAV  
$186.12
POP  
$196.95
NAV Change  
$1.80
NAV Change (%)  
0.98%
Date 
11/25/2025
NAV  
$184.32
POP  
$195.05
NAV Change  
$2.32
NAV Change (%)  
1.27%
Date 
11/24/2025
NAV  
$182.00
POP  
$192.59
NAV Change  
$4.14
NAV Change (%)  
2.33%
Date 
11/21/2025
NAV  
$177.86
POP  
$188.21
NAV Change  
$2.99
NAV Change (%)  
1.71%
Date 
11/20/2025
NAV  
$174.87
POP  
$185.05
NAV Change  
$-1.60
NAV Change (%)  
-0.91%
Date 
11/19/2025
NAV  
$176.47
POP  
$186.74
NAV Change  
$-0.77
NAV Change (%)  
-0.43%
Date 
11/18/2025
NAV  
$177.24
POP  
$187.56
NAV Change  
$2.78
NAV Change (%)  
—
Date 
11/17/2025
NAV  
$174.46
POP  
$184.61
NAV Change  
$4.82
NAV Change (%)  
2.84%
Date 
11/14/2025
NAV  
$169.64
POP  
$179.51
NAV Change  
$2.12
NAV Change (%)  
1.27%
Date 
11/13/2025
NAV  
$167.52
POP  
$177.27
NAV Change  
$-2.06
NAV Change (%)  
-1.21%
Date 
11/12/2025
NAV  
$169.58
POP  
$179.45
NAV Change  
$0.74
NAV Change (%)  
0.44%
Date 
11/11/2025
NAV  
$168.84
POP  
$178.67
NAV Change  
$5.18
NAV Change (%)  
3.17%

Documents

Product Literature

PDF Format

Factsheet - Franklin Biotechnology Discovery Fund

Regulatory Documents

PDF Format

Semi-Annual Report - Franklin Biotechnology Discovery Fund - Class A

PDF Format

Annual Report - Franklin Biotechnology Discovery Fund Class A

PDF Format

Prospectus - Franklin Strategic Series 2

PDF Format

Summary Prospectus - Franklin Biotechnology Discovery Fund

PDF Format

Statement of Additional Information - Franklin Strategic Series 2

Mailed hardcopies unavailable.

PDF Format

Fiscal Q1 Holdings - Franklin Strategic Series

Mailed hardcopies unavailable.

PDF Format

Fiscal Q3 Holdings - Franklin Strategic Series

Mailed hardcopies unavailable.

 

View Proxy Voting Records and Proxy Voting Policies

Risks

What Are the Risks?

All investments involve risks, including possible loss of principal. The portfolio is non-diversified and may invest in a relatively small number of issuers, which may negatively impact the fund's performance and result in greater fluctuation in the value of the fund's shares. To the extent the portfolio invests in a concentration of certain securities, regions or industries, it is subject to increased volatility. Small- and mid-cap stocks involve greater risks and volatility than large-cap stocks. International investments are subject to special risks, including currency fluctuations and social, economic and political uncertainties, which could increase volatility. These risks are magnified in emerging markets. The manager may consider environmental, social and governance (ESG) criteria in the research or investment process; however, ESG considerations may not be a determinative factor in security selection. In addition, the manager may not assess every investment for ESG criteria, and not every ESG factor may be identified or evaluated. These and other risks are discussed in the fund’s prospectus.

This website is intended for Primerica.
Copyright © 2025 Franklin Templeton. All Rights Reserved.